Drugs / Lamotrigine
last change Jan 2026 re-read 2 minutes ago

Lamotrigine

Small molecule targets HCN1 via activation

Developed for
epilepsy · bipolar disorder · bipolar depression · schizophrenia · focal epilepsy · depressive disorder · major depressive disorder · manic bipolar affective disorder
+36 more · alcohol dependence · bipolar I disorder · epilepsy with generalized tonic-clonic seizures · mood disorder · psychotic disorder · substance-related disorder · alcohol-related disorders · asthma · binge eating disorder · brain disorder · brain injury · chemotherapy-induced toxicity · childhood absence epilepsy · cognitive disorder · epilepsy syndrome · neurofibromatosis type 1 · neurotic disorder · obesity disorder · post-traumatic stress disorder · relapsing-remitting multiple sclerosis · secondary progressive multiple sclerosis · substance dependence · synaptopathy · trigeminal neuralgia · bipolar II disorder · borderline personality disorder · brain neoplasm · cocaine dependence · facial neuralgia · hyperkalemic periodic paralysis · Meniere disease · myotonic dystrophy type 1 · neurotic excoriation · nondystrophic myotonia · paramyotonia congenita of Von Eulenburg · potassium-aggravated myotonia
Investigated by
GlaxoSmithKline · National Institute of Mental Health (NIMH) · University of Cincinnati · Yale University · American Epilepsy Society · Assiut University
+82 more · Boehringer Ingelheim · Epilepsy Foundation · MaineHealth · Ministry of Health, Italy · Mylan Pharmaceuticals Inc · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institute on Drug Abuse (NIDA) · Teva Pharmaceuticals USA · Torrent Pharmaceuticals Limited · University Hospitals Cleveland Medical Center · University of Aarhus · University of Minnesota · Agios Pharmaceuticals, Inc. · Alliance for Clinical Trials in Oncology · Azienda Ospedaliera San Gerardo di Monza · Baylor College of Medicine · Beth Israel Medical Center · Bial - Portela C S.A. · Brown University · Cantonal Hospital of St. Gallen · Central Mental Clinic for Outpatients of Baku City · Centre of Chinese Medicine, Georgia · Chang Gung Memorial Hospital · Charite University, Berlin, Germany · Chinese University of Hong Kong · Dr. Reddy's Laboratories Limited · Dutch Epilepsy Clinics Foundation · Eli Lilly and Company · Emory University · Erasmus Medical Center · Federal University of Rio Grande do Sul · Glaxo Wellcome · Hannover Medical School · Hospital Sant Joan de Deu · Hospital de Clinicas de Porto Alegre · IRCCS National Neurological Institute "C. Mondino" Foundation · International Brain Research Foundation · Karuna Therapeutics, Inc. · Korean Epilepsy Society · Lindner Center of HOPE · Louisiana State University Health Sciences Center in New Orleans · Mario Negri Institute for Pharmacological Research · Massachusetts General Hospital · Mclean Hospital · Medical University of South Carolina · Merck Sharp & Dohme LLC · National Alliance for Research on Schizophrenia and Depression · National Cancer Institute (NCI) · National Center for Research Resources (NCRR) · National Taiwan University Hospital · Parke-Davis · Per Damkier · Radboud University Medical Center · Rambam Health Care Campus · Rea Rehabilitation Centre, Georgia · Rhode Island Hospital · Robert Wood Johnson Foundation · Seoul National University Hospital · St. Petersburg State Pavlov Medical University · Stanford University · Stanley Medical Research Institute · Stony Brook University · Taipei City Hospital · Technical University of Munich · The Dana Foundation · The University of Texas Health Science Center at San Antonio · UCB Biopharma S.P.R.L. · US Department of Veterans Affairs · Universitaire Ziekenhuizen KU Leuven · University College London Hospitals · University Health Network, Toronto · University Hospital, Rouen · University Magna Graecia · University of Illinois at Chicago · all 88 on the full record

Regulatory milestones approvals, filings & regulatory actions · 10 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) LAMICTAL ODT 2015-05-18 fda.gov
Label expansion US (FDA) LAMICTAL XR 2011-04-25 fda.gov
Label expansions (6) US (FDA) LAMICTAL CD 1998-12-14 – 2006-09-22 fda.gov
Label expansion US (FDA) LAMICTAL 1998-08-24 fda.gov
Approved US (FDA) LAMICTAL 1994-12-27 fda.gov

Trials 106 · started per year

today
US approved 1994
1
1
1
2
3
2
8
10
9
6
10
4
9
2
2
4
4
2
3
4
2
3
1
2
2
2
1
2
19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 119 trials
Phase 1 NCT06729970 Dec 2024 → Jan 2026 Karuna Therapeutics, Inc. Completed No outcome recorded
Phase 1 NCT04602221 Dec 2020 → Aug 2022 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04015687 Jul → Oct 2019 Agios Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1 NCT03695094 Sep 2018 → May 2019 epilepsy UCB Biopharma S.P.R.L. Completed No outcome recorded
Phase 1 NCT02513654 Sep → Nov 2015 bipolar disorder GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT02708849 Jun 2015 → Mar 2020 mental disorder Yale University Terminated No outcome recorded
Phase 1 NCT01888757 Sep 2010 Dr. Reddy's Laboratories Limited Completed No outcome recorded
Phase 1 NCT00907985 May 2009 → Jun 2010 bipolar disorder GlaxoSmithKline Terminated No outcome recorded
Phase 1 NCT01607086 Jul 2008 mental disorder GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00618241 Feb → Oct 2008 HIV infectious disease Radboud University Medical Center Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT02696512 Mar 2016 → Mar 2017 brain injury International Brain Research Foundation Unknown No outcome recorded
Phase 1/2 NCT00789113 Nov 2008 → Jan 2011 bipolar depression, epilepsy University of Minnesota Completed No outcome recorded
Phase 213 trials
Phase 2 NCT04770493 Jan 2022 → Oct 2023 alcohol-related disorders Brown University Completed No outcome recorded
Phase 2 NCT03504501 Mar 2019 → Feb 2023 cognitive disorder, synaptopathy Technical University of Munich Terminated No outcome recorded
Phase 2 NCT03220256 Aug 2016 → Aug 2018 Seoul National University Hospital Unknown No outcome recorded
Phase 2 NCT00917839 Jun 2009 → Dec 2010 relapsing-remitting multiple sclerosis Cantonal Hospital of St. Gallen Unknown No outcome recorded
Phase 2 NCT00269594 Jan → Sep 2006 neurotic disorder, obsessive-compulsive disorder University of Minnesota Completed No outcome recorded
Phase 2 NCT00257855 Nov 2005 → Jan 2009 secondary progressive multiple sclerosis University College London Hospitals Completed No outcome recorded
Phase 2 NCT00176228 Feb 2004 → Jan 2008 bipolar disorder University of Illinois at Chicago Completed No outcome recorded
Phase 2 NCT00206778 Jul 2003 → Jul 2007 manic bipolar affective disorder Beth Israel Medical Center Completed No outcome recorded
Phase 2 NCT00044278 Sep 2000 → Jun 2006 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00043875 May 2000 → Nov 2003 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 2/33 trials
Phase 2/3 NCT02556060 Sep 2015 → May 2017 substance dependence Taipei City Hospital Completed No outcome recorded
Phase 2/3 NCT02256124 Oct 2014 → Apr 2020 neurofibromatosis type 1 Erasmus Medical Center Terminated No outcome recorded
Phase 2/3 NCT00913107 Sep 2007 → Feb 2008 trigeminal neuralgia University of Malaya Completed No outcome recorded
Phase 326 trials
Phase 3 NCT02374567 Jan 2015 → Jun 2017 anxiety disorder, dementia, depressive disorder, schizophrenia +1 Hannover Medical School Terminated No outcome recorded
Phase 3 NCT01602510 Aug 2012 → Dec 2015 bipolar I disorder GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00571246 Jun 2012 → Jun 2016 alcohol dependence, post-traumatic stress disorder Yale University Withdrawn No outcome recorded
Phase 3 NCT01431976 Sep 2011 → Feb 2014 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT01431963 Sep 2011 → Mar 2013 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00723450 Jul 2008 → Aug 2013 bipolar disorder GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00566020 May 2008 → Oct 2010 bipolar I disorder GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00621842 Jan 2008 → Mar 2010 bipolar depression University Hospitals Cleveland Medical Center Completed No outcome recorded
Phase 3 NCT00579982 Jan → Feb 2008 mood disorder GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00516139 Aug 2007 → Jul 2010 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 428 trials
Phase 4 NCT05881928 Jul 2024 overdue epilepsy Assiut University Not yet recruiting No outcome recorded
Phase 4 NCT03689114 May 2021 → Jun 2024 focal epilepsy Mario Negri Institute for Pharmacological Research Completed No outcome recorded
Phase 4 NCT03161509 Jul 2017 → Dec 2018 Rambam Health Care Campus Terminated No outcome recorded
Phase 4 NCT02303106 Nov 2014 → Apr 2015 Per Damkier Completed No outcome recorded
Phase 4 NCT02100644 Apr 2014 → May 2015 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT01713777 Apr 2013 → Sep 2015 epilepsy University of Cincinnati Completed No outcome recorded
Phase 4 NCT01733394 Dec 2012 → Sep 2016 epilepsy University of Cincinnati Completed No outcome recorded
Phase 4 NCT02429596 May 2012 → May 2015 epilepsy IRCCS National Neurological Institute "C. Mondino" Foundation Unknown No outcome recorded
Phase 4 NCT01015586 Feb 2010 → May 2014 alcohol dependence, depressive disorder, manic bipolar affective disorder, psychotic disorder Medical University of South Carolina Completed No outcome recorded
Phase 4 NCT00807989 Mar 2008 → May 2012 epilepsy Yonsei University Completed No outcome recorded
Phase not applicable14 trials
NCT04939675 Jul 2021 → Jun 2023 epilepsy National Taiwan University Hospital Unknown No outcome recorded
NCT04156035 Mar → Dec 2020 Charite University, Berlin, Germany Completed No outcome recorded
NCT04396938 May 2017 → Nov 2018 University of Oxford Completed No outcome recorded
NCT05236166 Apr 2017 → May 2021 epilepsy University Magna Graecia Completed No outcome recorded
NCT02556320 May 2013 → Aug 2015 drug allergy, epilepsy University Hospital, Rouen Completed No outcome recorded
NCT01880957 Nov 2011 → Jun 2017 bipolar depression, major depressive disorder Stony Brook University Completed No outcome recorded
NCT01463111 May 2011 → Apr 2016 bipolar disorder Emory University Completed No outcome recorded
NCT00531518 Oct 2007 → May 2013 bipolar disorder, depressive disorder, schizophrenia MaineHealth Completed No outcome recorded
NCT00720473 Apr 2006 → Jul 2011 bipolar depression Mclean Hospital Completed No outcome recorded
NCT00284791 Jan 2006 → Feb 2007 MaineHealth Terminated No outcome recorded
Phase not stated1 trial
NCT03419949 Assiut University Available No outcome recorded
Also used as a comparator or background therapy in 49 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT05145608 Comparator Jan → Feb 2018 Alembic Pharmaceuticals Ltd. Completed No outcome recorded
Phase 1 NCT02707965 Comparator Jun 2017 → Aug 2018 epilepsy Food and Drug Administration (FDA) Completed No outcome recorded
Phase 1 NCT02821338 Comparator Jun → Sep 2016 Food and Drug Administration (FDA) Completed No outcome recorded
Phase 1 NCT02081287 Comparator May 2014 → Jul 2018 manic bipolar affective disorder San Diego Veterans Healthcare System Completed No outcome recorded
Phase 1 NCT00627575 Comparator Feb → Sep 2008 epilepsy GlaxoSmithKline Completed No outcome recorded
Phase 25 trials
Phase 2 NCT05420350 Comparator Dec 2020 → Jul 2024 Meniere disease Dent Neuroscience Research Center Unknown No outcome recorded
Phase 2 NCT02158585 Comparator Jun 2014 → Mar 2017 Meniere disease Dent Neuroscience Research Center Completed No outcome recorded
Phase 2 NCT01674010 Background Aug 2012 → Jun 2014 bipolar I disorder OPKO Health, Inc. Terminated No outcome recorded
Phase 2 NCT00475137 Comparator Dec 2007 → Jun 2015 bipolar II disorder University of British Columbia Completed No outcome recorded
Phase 2 NCT00513019 Comparator Aug 2007 → Aug 2009 neurotic excoriation University of Chicago Completed No outcome recorded
Phase 315 trials
Phase 3 NCT06929273 Background Jul 2025 → Jun 2028 expected bipolar I disorder Bristol-Myers Squibb Recruiting No outcome recorded
Phase 3 NCT05017155 Comparator Aug 2021 → Aug 2023 nondystrophic myotonia University College, London Unknown No outcome recorded
Phase 3 NCT04274179 Comparator Aug 2020 → May 2028 expected childhood absence epilepsy Johns Hopkins University Recruiting No outcome recorded
Phase 3 NCT03831854 Comparator Jan 2019 → Dec 2020 The Cleveland Clinic Completed No outcome recorded
Phase 3 NCT01939561 Comparator Nov 2013 → Nov 2015 hyperkalemic periodic paralysis, myotonic dystrophy type 1, paramyotonia congenita of Von Eulenburg, potassium-aggravated myotonia Grete Andersen, MD Completed No outcome recorded
Phase 418 trials
Phase 4 NCT06184581 Comparator May 2024 → Dec 2027 expected bipolar II disorder University Hospital Bispebjerg and Frederiksberg Recruiting No outcome recorded
Phase 4 NCT05697614 Comparator Mar → May 2023 epilepsy Dr Cipto Mangunkusumo General Hospital Unknown No outcome recorded
Phase 4 NCT05748236 Comparator Nov 2022 → Oct 2023 focal epilepsy Dhaka Medical College Unknown No outcome recorded
Phase 4 NCT02670161 Comparator May 2016 → Dec 2026 expected Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 Endeavor Health Enrolling by invitation No outcome recorded
Phase 4 NCT02404168 Comparator Jul 2015 → Jan 2016 epilepsy University of Maryland, Baltimore Completed No outcome recorded
Phase not applicable6 trials
NCT05639257 Comparator Dec 2022 → Apr 2024 nondystrophic myotonia Grete Andersen, MD Unknown No outcome recorded
NCT03636958 Background Feb 2021 → Jul 2025 epilepsy Assistance Publique Hopitaux De Marseille Withdrawn No outcome recorded
NCT02300051 Background Feb 2011 → Apr 2015 sexual disorder University of Sao Paulo General Hospital Completed No outcome recorded
NCT00916149 Comparator Jan 2007 → Oct 2012 epilepsy Massachusetts General Hospital Completed No outcome recorded
NCT00243152 Comparator Oct 2005 → Jul 2008 facial neuralgia Pain and Analgesia Imaging and Neuroscience Group Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2008-07-23 Teva Branded Pharmaceutical Products R&D, Inc. Teva Introduces First Generic Lamictal® Tablets in the United States tevapharm.com
2005-02-17 Teva Branded Pharmaceutical Products R&D, Inc. Teva Announces Settlement Of Lamictal® Litigation With Glaxosmithkline tevapharm.com

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 161 sources stand behind the page.

FieldValueCited text
Known as lamotrigine “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526
151

“Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512

“Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958

“In this study, we evaluated the efficacy and occurrence of side effects of lamotrigine (LTG) in comparison with carbamazepine (CBZ), in trigeminal neuralgia (TN) patients.” PMID 21621166 May 2011

“The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome” NCT00241995

“Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)” NCT02556320

“This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures.” NCT00113165

“mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).” NCT02300051

Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study.” PMID 26518979 Oct 2015

“Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide” NCT05236166

“The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate” NCT00947375

“carbamazepine, valproic acid, topiramate, oxcarbazepine, levetiracetam or lamotrigineNCT02429596

“Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy” NCT01431963

Lamotrigine (according to response, and tolerance)25-200mg” NCT01000402

“brain tumors (lamotrigine, levetiracetam, valproic acid)” NCT02670161

“Ethosuximide, valproate or lamotrigineNCT04274179

“Lamictal (lamotrigine)” NCT00269594

LamotrigineNCT02205931

NCT01888757

NCT00242606

NCT04602221

NCT05017155

NCT00280293

NCT04523935

NCT00044278

NCT00243152

NCT01588457

NCT00104416

NCT00206778

NCT01602510

NCT02556060

NCT00838136

NCT02256124

NCT06929273

NCT01015586

NCT00621842

NCT04770493

NCT05748236

NCT02707965

NCT01674010

NCT00277212

NCT02513654

NCT00144872

NCT00137709

NCT00264615

NCT00280059

NCT02821338

NCT06729970

NCT00516139

NCT00566020

NCT03831854

NCT00074776

NCT02374567

NCT00550407

NCT02303106

NCT00001482

NCT00208520

NCT00007670

NCT02404168

NCT00917839

NCT00939458

NCT00188643

NCT00579982

NCT02389712

NCT00939614

NCT00360126

NCT00015106

NCT00896987

NCT02283801

NCT00067938

NCT00223262

NCT00618241

NCT00916149

NCT00086593

NCT00720473

NCT00627575

NCT00181844

NCT00153244

NCT02081287

NCT00438451

NCT00266149

NCT00634062

NCT00223509

NCT05145608

NCT01713777

NCT00907985

NCT01880957

NCT00475137

NCT00274677

NCT00177567

NCT02100644

NCT02989727

NCT00063362

NCT00355082

NCT00652171

NCT01891890

NCT00855738

NCT04015687

NCT00789113

NCT04156035

NCT03689114

NCT03504501

NCT02158585

NCT00043914

NCT00088452

NCT00226135

NCT00257855

NCT01939561

NCT03161509

NCT00292461

NCT03695094

NCT02708849

NCT00838279

NCT00000192

NCT00068445

NCT01042496

NCT05697614

NCT00203229

NCT00043901

NCT00183469

NCT01607086

NCT00012558

NCT03220256

NCT01463111

NCT00056277

NCT05420350

NCT00647751

NCT06184581

NCT01142310

NCT03419949

NCT04939675

NCT00221975

NCT00419003

NCT04396938

NCT00410371

NCT00650208

NCT00071747

NCT00176228

NCT00485771

NCT00224510

NCT01864551

NCT05881928

NCT00926835

NCT00901407

NCT00807989

NCT01733394

NCT00277641

NCT00043875

NCT00571246

NCT00531518

NCT00284791

NCT05639257

Known as 430C78 “The objective of this sensory analysis study is to determine whether volunteers observe a significant difference in organoleptic properties between lamotrigine (430C78) cherry...” NCT01607086
Known as BW430C BW430C (lamotrigine)” NCT00566020
Known as Lamictal “The objective of this study was to investigate the bioequivalence of Mylan's lamotrigine 25 mg tablets to GlaxoSmithKline's (GSK) Lamictal® 25 mg tablets following a single,...” NCT00650208
19

“This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of...” NCT00044278

“The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional...” NCT00243152

“Baclofen(Liofen®),Diazepam,(Valium®),Clonazepam,(Klonopin®),Trihexyphenidyl(Artane®),Tetrabenazine(Xenazine®),Gabapentin(Neurontin®),Topiramate(Topamax®),Lamotrigine(Lamictal®),...” NCT04523935

“A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed...” NCT00280059

“A Multicentre, Double-Blind, Randomised, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine (Lamictal) compared to placebo as add-on therapy to lithium” NCT00224510

“switched from your regular lamotrigine (Lamictal®) to once daily morning dosing of an extended-release formulation of Lamictal-XR® (at the same total daily dose).” NCT00789113

“This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures.” NCT00113165

“The study drug Lamictal® (lamotrigine) and both of the generic forms of lamotrigine to be tested are approved by the FDA for the treatment of seizures.” NCT01733394

“This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.” NCT00074776

“Lamotrigine (Lamictal®) recently gained approval by the FDA for maintenance treatment of bipolar disorder in adults.” NCT00284791

Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA” NCT00939458

“Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal).” NCT00181844

Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA” NCT00939614

Lamictal® was used as the "active" medication in this study.” NCT00913107

“lamotrigine (LAMICTAL) extended-release” NCT00104416

NCT00269594

NCT00723450

NCT00513019

NCT00395694

Known as Lamictal (Registered Trademark) “Lamotrigine (Lamictal® (Registered Trademark)” NCT00001482
Known as Lamictal cd ChEMBL registry synonym — accepted as the source's own label CHEMBL741
Known as Lamictal odt ChEMBL registry synonym — accepted as the source's own label CHEMBL741
Known as Lamictal-XR “switched from your regular lamotrigine (Lamictal®) to once daily morning dosing of an extended-release formulation of Lamictal-XR® (at the same total daily dose).” NCT00789113
Known as Lamotrigina ChEMBL registry synonym — accepted as the source's own label CHEMBL741
Known as Lamotrigine (generic name for Lamictal) “Lamotrigine (generic name for Lamictal®)” NCT00913107
Known as Lamotrigine Generic "A" “Drug: Lamotrigine Generic "A"NCT01713777
Known as Lamotrigine generic "B" “Drug: Lamotrigine generic "B"NCT01713777
Known as LTG “To evaluate the tolerability and efficacy of levetiracetam (LEV) in newly diagnosed elderly patients (aged 60 yrs or above) with focal epilepsy compared to lamotrigine (LTG) or...” NCT00438451
9

“Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once...” NCT02100644

“In animal studies, pathway-specific pharmacological interventions with lovastatin (LOV) and lamotrigine (LTG) have been shown to improve synaptic plasticity as well as...” PMID 37280688 Jun 2023

“PURPOSE: To evaluate the efficacy and safety of lamotrigine (LTG) monotherapy for treating Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures.” PMID 26518979 Oct 2015

“This is an open-label study evaluating the efficacy and safety of lamotrigine (LTG) for the treatment of newly-diagnosed typical absence seizures.” NCT00144872

“The objective of this study was to compare lamotrigine (LTG) and lithium (Li) monotherapy for the treatment of BDII depression.” PMID 18358540 Mar 2008

“This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy.” NCT00516139

“Lamotrigine (LTG) is a second generation AED , and also has the function of resisting depression and stabilizing mood .” NCT05881928

“example anti epilepsy drug (AED) used for this study will be lamotrigine (LTG).” NCT01733394

“lamotrigine (LTG)” PMID 22595362 May 2012

Known as NSC-759171 ChEMBL registry synonym — accepted as the source's own label CHEMBL741
Known as Reference- Lamictal XRTM (Lamotrigine) ER tablet 50mg “Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg” NCT05145608
Action Inhibit “Lamotrigine, a phenyltriazine use-dependent sodium channel blocker that inhibits release of excitatory amino acids” NCT00001482
Modality Small molecule CHEMBL741
Route Oral “Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks.” NCT00068445
Target HCN1 “Lamotrigine, an HCN1-agonist, rescued this electrophysiological phenotype in an NF1 mouse model.” PMID 40121838 Mar 2025